Please login to the form below

Not currently logged in
Email:
Password:

dolutegravir

This page shows the latest dolutegravir news and features for those working in and with pharma, biotech and healthcare.

ViiV chalks up another win for two-drug HIV regimen

ViiV chalks up another win for two-drug HIV regimen

few years due to the success of drugs like oral integrase inhibitor Tivicay (dolutegravir) and triple regimen Triumeq (dolutegravir/lamivudine/abacavir). ... effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside

Latest news

More from news
Approximately 8 fully matching, plus 45 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company’ s HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics